Skip to main content

Foose Brice's Form 4 filing

Invivo Therapeutics Holdings Corp. (NVIV) · filed Feb 7, 2024

Accession no.
0001974830-24-000001
Filed
Feb 7, 2024, 1:31 PM ET
Trade date
Feb 5-6, 2023
Filing delay
367 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 11 non-derivative transactions. Open-market purchases total $123.0K. It was filed 367 days after the trade, past the 2-business-day deadline.

This filing was later replaced by the amendment 0001974830-24-000002 (Feb 7, 2024). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Foose BriceCIK 000197483010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 5, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−37,000$0.31−$11,470293,000Direct
Feb 5, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−20,000$0.32−$6,400273,000Direct
Feb 5, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−13,000$0.30−$3,900260,000Direct
Feb 5, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−48,000$0.28−$13,440212,000Direct
Feb 5, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−12,000$0.25−$3,000200,000Direct
Feb 5, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−36,000$0.26−$9,360164,000Direct
Feb 6, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−8,000$0.34−$2,720156,000Direct
Feb 6, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−33,000$0.35−$11,550123,000Direct
Feb 6, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−35,000$0.36−$12,60088,000Direct
Feb 6, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−37,000$0.50−$18,50051,000Direct
Feb 6, 2023InVivo Therapeutics Holdings CorpPPurchaseDisposed−51,000$0.59−$30,0900Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)